Aging, Bone Loss
Conditions
Keywords
adrenergic
Brief summary
This protocol addresses: 1) How gene expression changes in bone cells are affected by aging? 2) Is aging associated with decreased signaling between bone cells? 3) How does treatment with the osteoporosis medication denosumab affect bone cell signaling?
Detailed description
This protocol collectively addresses the following goals: 1) What are the changes in gene expression in osteoblasts and osteocytes that lead to impaired bone formation with aging; 2) Since recent work from the investigators' group has demonstrated that osteoclasts produce a number of growth factors and cytokines (coupling factors) that enhance osteoblast proliferation and/or differentiation, is aging associated with reduced osteoclast coupling factor production; and 3) If osteoclasts are markedly reduced using the FDA-approved medication for osteoporosis, denosumab, how does that effect the quantity of coupling factors in the bone microenvironment and the target genes of these coupling factors in osteoblasts?
Interventions
DRUGplacebo
subcutaneous saline injection
DRUGdenosumab
single subcutaneous injection of denosumab 60 mg
Sponsors
Mayo Clinic
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
25 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Inclusion Criteria: * normal premenopausal women aged 25-40 years * normal postmenopausal women aged 60-80 years * at least 5 yrs since their last menses * follicle stimulating hormone (FSH) \> 20 IU/L *
Exclusion criteria
* Abnormality in any of the screening laboratory studies * Presence of significant liver or renal disease * Malignancy (including myeloma) * Malabsorption * Diabetes * Hypoparathyroidism * Hyperparathyroidism * Acromegaly * Cushing's syndrome * Hypopituitarism * Severe chronic obstructive pulmonary disease * Undergoing treatment with any medications that affect bone turnover, including the following: * adrenocorticosteroids (\> 3 months at any time or \> 10 days within the previous yr) * anticonvulsant therapy (within the previous year) * pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal) * calcium supplementation of \> 1200 mg/d (within the preceding 3 months) * bisphosphonates (within the past 3 yrs) * denosumab * estrogen (E) therapy within the past year * treatment with a selective E receptor modulator within the past year * teriparatide within the past yr * Clinical history of osteoporotic fracture (vertebral, hip, or distal forearm) * Recent (within the past 6 months) fracture * Serum 25-hydroxyvitamin D levels of \< 20 ng/ml
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gene expression changes in bone cells | 3 months | Ratio of selected genes as expressed between each of the 3 arms (i.e. relative runx2 gene expression levels in each arm). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Osteoclast-osteoblast coupling factor changes | 3 months | Ratio of selected genes as expressed between each of the 3 arms (i.e. relative runx2 gene expression levels in each arm). |
Countries
United States
Outcome results
None listed